OTCMKTS:IPSEY

Ipsen (IPSEY) Stock Forecast, Price & News

$34.00

0.00 (0.00%)

(As of 09/20/2023 ET)

Compare

Today's Range: $34.00
▼
$34.00
50-Day Range: $29.53
▼
$34.34
52-Week Range: $21.35
▼
$34.34

Volume: 187 shs
Average Volume: 281 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: 0.68%
Price Target: $30.60

Profile Analyst Ratings Chart Competitors Dividend Headlines Short Interest

Ipsen MarketRank™ Forecast

Analyst Rating: Hold
2.38 Rating Score
Upside/Downside: 10.0% Downside
$30.60 Price Target
Short Interest: Healthy
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: 0.57
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 10.36%
From $2.51 to $2.77 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.68 out of 5 stars

1.2

Analyst's Opinion

Consensus Rating
Ipsen has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 3 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.60, Ipsen has a forecasted downside of 10.0% from its current price of $34.00.
Amount of Analyst Coverage
Ipsen has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
Short Interest Ratio / Days to Cover
Ipsen has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ipsen has recently decreased by 50.00%, indicating that investor sentiment is improving significantly.

0.8

Dividend Strength

Dividend Yield
Ipsen has a dividend yield of 0.68%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Ipsen does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, Ipsen will have a dividend payout ratio of 8.30% next year. This indicates that Ipsen will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IPSEY.

2.5

News and Social Media Coverage

News Sentiment
Ipsen has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Ipsen this week, compared to 1 article on an average week.

N/A

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ipsen insiders have not sold or bought any company stock.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Ipsen are expected to grow by 10.36% in the coming year, from $2.51 to $2.77 per share.
Price to Book Value per Share Ratio
Ipsen has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ipsen (OTCMKTS:IPSEY) Stock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome or chronic renal insufficiency, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Xermelo for the treatment of carcinoid syndrome; and Cometriq to treat medullary thyroid cancer. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

IPSEY Price History

30 days | 90 days | 365 days | Advanced Chart

IPSEY Stock News Headlines

September 17, 2023 | msn.com

Ipsen celebrates 75 years of its location in Cherry Valley

September 15, 2023 | americanbankingnews.com

Ipsen S.A. (OTCMKTS:IPSEY) Receives $30.60 Average Target Price from Brokerages

September 21, 2023 | Behind the Markets (Ad)

The World's First "$20 Trillion Drug

?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>

September 13, 2023 | americanbankingnews.com

Ipsen (OTCMKTS:IPSEY) Upgraded to Buy at UBS Group

September 12, 2023 | americanbankingnews.com

Ipsen (OTCMKTS:IPSEY) Shares Pass Above 200-Day Moving Average of $30.01

September 1, 2023 | finance.yahoo.com

Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet

August 21, 2023 | msn.com

Exelixis lead product hits main goal in Phase 3 prostate cancer trial

August 17, 2023 | msn.com

US FDA approves French drugmaker Ipsen's rare bone disorder drug

September 21, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

August 16, 2023 | bloomberg.com

US Approves Ipsen’s Therapy for Rare Bone Disease

August 16, 2023 | usnews.com

US FDA Approves Ipsen's Rare Bone Disorder Drug

August 16, 2023 | finance.yahoo.com

US FDA approves Ipsen’s SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

July 28, 2023 | finanznachrichten.de

Ipsen Pharma: Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

July 27, 2023 | marketwatch.com

Ipsen Shares Rise After It Upgrades 2023 Outlook

July 27, 2023 | finance.yahoo.com

Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

July 24, 2023 | finance.yahoo.com

Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023

July 21, 2023 | marketwatch.com

Ipsen's Bylvay for Alagille Syndrome Recommended for Approval by EU Agency

July 21, 2023 | finance.yahoo.com

Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome

July 19, 2023 | finanznachrichten.de

Ipsen Pharma: Ipsen announces European Commission decision on palovarotene for the treatment of FOP

July 19, 2023 | uk.finance.yahoo.com

Ipsen announces European Commission decision on palovarotene for the treatment of FOP

June 30, 2023 | markets.businessinsider.com

Genfit's Miss Is CymaBay Therapeutics' Gain: Analyst Says Rival Data Leaves Room for Seladelpar To Emerge As Best-In-Class

June 30, 2023 | msn.com

Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients

June 29, 2023 | finanznachrichten.de

Ipsen Pharma: Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva

June 29, 2023 | markets.businessinsider.com

FDA Panel Votes In Favor Of Ipsen's Palovarotene For Ultra-rare Bone Disease

June 29, 2023 | finance.yahoo.com

Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva

June 28, 2023 | bloomberg.com

Ipsen Gets FDA Advisers’ Backing for Rare Bone Disease Therapy

June 14, 2023 | msn.com

Mirum falls as FDA expands label for Ipsen’s liver disease therapy

See More Headlines

Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

IPSEY Company Calendar

Ex-Dividend for 6/27 Dividend: 6/02/2023
Dividend Payable: 6/27/2023
Today: 9/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Diagnostic substances
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:IPSEY
CUSIP: N/A
CIK: N/A
Web: www.ipsen.com
Phone: (315) 833-5000
Fax: 33-01-58-33-50-01
Employees: 5,300
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $30.60
High Stock Price Forecast: $30.60
Low Stock Price Forecast: $30.60
Forecasted Upside/Downside: -10.0%
Consensus Rating: Hold
Rating Score (0-4): 2.38
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.80
Quick Ratio: 1.58

Sales & Book Value

Annual Sales: $3.33 billion
Price / Sales: N/A
Cash Flow: $3.51 per share
Price / Cash Flow: 9.68
Book Value: $9.72 per share
Price / Book: 3.50

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 0.98

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. David Loew (Age 56)
MD, CEO & Director
Comp: $2.38M

Mr. Aymeric Le Chatelier (Age 54)
Exec. VP & Group CFO

Dr. Aidan Murphy Ph.D. (Age 57)
Exec. VP of Technical Operations

Mr. Craig Marks
Vice-Pres of Investor Relations

Mr. Francois Garnier (Age 61)
Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer

Ms. Gwenan White
Exec. VP of Communications, Public Affairs & Sustainability

Mr. Regis Mulot (Age 57)
Exec. VP & Chief HR Officer

Ms. Dominique Bery (Age 52)
Head of Nordics & Baltics

Dr. Yan Moore M.D. (Age 56)
Sr. VP & Head of Oncology Therapeutic Area

Dr. Alexander McEwan
Vice-Pres & Head of Radiopharmaceuticals

Key Competitors

View All Competitors

IPSEY Stock - Frequently Asked Questions

Should I buy or sell Ipsen stock right now?: 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IPSEY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPSEY, but not buy additional shares or sell existing shares.
View IPSEY analyst ratings or view top-rated stocks.
What is Ipsen's stock price forecast for 2023?: 8 Wall Street analysts have issued 12 month target prices for Ipsen's stock. Their IPSEY share price forecasts range from $30.60 to $30.60. On average, they anticipate the company's share price to reach $30.60 in the next year. This suggests that the stock has a possible downside of 10.0%.
View analysts price targets for IPSEY or view top-rated stocks among Wall Street analysts.
How have IPSEY shares performed in 2023?: Ipsen's stock was trading at $26.88 at the beginning of the year. Since then, IPSEY shares have increased by 26.5% and is now trading at $34.00.
View the best growth stocks for 2023 here.
Are investors shorting Ipsen?: Ipsen saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 100 shares, a decrease of 50.0% from the August 15th total of 200 shares. Based on an average daily volume of 800 shares, the short-interest ratio is presently 0.1 days.
View Ipsen's Short Interest.
How often does Ipsen pay dividends? What is the dividend yield for Ipsen?: Ipsen announced a dividend on Thursday, June 1st. Stockholders of record on Monday, June 5th will be given a dividend of $0.2337 per share on Tuesday, June 27th. This represents a yield of 0.8%. The ex-dividend date is Friday, June 2nd. This is an increase from the stock's previous dividend of $0.23.
Read our dividend analysis for IPSEY.

Is Ipsen a good dividend stock?: Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.23 per share and currently has a dividend yield of 0.68%.
Read our dividend analysis for IPSEY.
What is Ipsen's stock symbol?: Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY."
How do I buy shares of Ipsen?: Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ipsen's stock price today?: One share of IPSEY stock can currently be purchased for approximately $34.00.
How many employees does Ipsen have?: The company employs 5,300 workers across the globe.
How can I contact Ipsen?: Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The official website for the company is www.ipsen.com. The company can be reached via phone at (315) 833-5000, via email at investor.relations@ipsen.com, or via fax at 33-01-58-33-50-01.

This page (OTCMKTS:IPSEY) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial